Compare UTSI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTSI | MDXH |
|---|---|---|
| Founded | 1991 | 2003 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 21.1M |
| IPO Year | 1999 | 2021 |
| Metric | UTSI | MDXH |
|---|---|---|
| Price | $2.42 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 13.8K | ★ 269.2K |
| Earning Date | 03-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.40 |
| 52 Week High | $3.63 | $5.33 |
| Indicator | UTSI | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 47.46 |
| Support Level | $2.25 | $0.40 |
| Resistance Level | $2.56 | $3.79 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 42.50 | 69.41 |
UTStarcom Holdings Corp is engaged in providing telecommunication and networking products, solutions and services, focusing on optical networking, carrier-class packet optical, network synchronization, broadband products and a Software Defined Networking (SDN) platform optimized for AI networking infrastructure, mobile backhaul, metro aggregation, broadband access and value-added services. The Company operates through two segments: Equipment, which includes the sale of network infrastructure and application products such as broadband and wireless infrastructure technologies, and Services, which generates maximum revenue and provides support and operational services for equipment products. The Company generates maximum revenue from Japan.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.